Biotech companies at World ADC London 2027

Mar 8–11, 2027 London, UK ~700 attendees Website

16 biotech companies are at World ADC London 2027 — 13 presentations on the program. Most represented: Iksuda Therapeutics (2 on the program), VAR2 Pharmaceuticals (2 on the program), Oxford BioTherapeutics (1 on the program). 3 of them have their own page in this guide. As of Oct 8, 2026.

All 75 organizations at World ADC London 2027 →

Showing 1–16 of 16 organizations

Organization	World ADC London 2027 Attendance
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Araris Biotech, Oxford BioTherapeutics, Boehringer Ingelheim Clinical development Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Callio Therapeutics ADC discoveryClinical development Talk Novel ADC Designs Drive Improved Clinical Outcomes Clinical Lessons ADC discovery Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Oxford BioTherapeutics ADC discovery
VAR2 Pharmaceuticals Copenhagen, Denmark
var2pharma.com Biotech Clinical-stage Danish biotech, spun out of the University of Copenhagen, developing therapies that target cancer-specific glycosaminoglycans.	Talk From Target to Clinic – Development & Manufacturing of the First in Class VARTUMAB ADC Manufacturing & Supply Chain ADC discovery Also Presenting at the meeting, beyond the sessions above
Oxford BioTherapeutics Oxford, UK
oxfordbiotherapeutics.com Biotech Oncology biotech discovering new cancer targets and developing antibody and ADC therapies, including the CD205-directed ADC OBT076.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Araris Biotech, Boehringer Ingelheim Clinical development Workshop Thu Mar 11 1:00pm Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design Post-conference workshop for Clinical Lessons · with Iksuda Therapeutics ADC discovery
Araris Biotech
ararisbiotech.com Biotech Swiss biotech developing antibody-drug conjugates, including multi-payload conjugates, with a linker that attaches payloads to unmodified antibodies.	Panel Tue Mar 9 9:30am CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies Plenary · with Iksuda Therapeutics, Oxford BioTherapeutics, Boehringer Ingelheim Clinical development
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, University of Michigan, Iksuda Therapeutics ADC discoveryClinical development
InduPro
induprotx.com Biotech Biotech developing antibody-drug conjugates against a new class of targets it calls TAPAs.	Talk TAPAs: A New Class of ADC Targets From Discovery to the Clinic Discovery Clinical development
LigaChem Biosciences Daejeon, South Korea
ligachembio.com Biotech Korean biotech developing ADCs on its site-specific conjugation platform, including a CLDN18.2-targeted candidate, and licensing the technology to partners.	Talk Advancing In Vitro Model Selection for Bone Marrow, Liver & Lung to Test Pre Clinical Activity & Toxicity Preclinical & Translational
SalubrisBio Gaithersburg, MD
salubrisbio.com Biotech Develops biologics for oncology and heart failure, including JK06, a biparatopic 5T4-targeted ADC with an MMAE payload.	Talk JK06 Biparatopic 5T4-Targeted MMAE ADC: Overcoming the Challenges of a Difficult Target Through Rational Design Clinical Lessons ADC discovery
Tagworks Pharmaceuticals Nijmegen, Netherlands
tagworkspharma.com Biotech Develops click-to-release cancer therapies in which a separate trigger frees the payload from tumor-bound ADCs, led by TGW101.	Talk Discovery & Development of Click-To-Release ADCs With Enhanced Therapeutic Potential Discovery
BioNTech Mainz, Germany
biontech.com Biotech Develops mRNA vaccines and cancer immunotherapies, including antibody-drug conjugates.	Also Presenting at the meeting, on no published session yet
Byondis Nijmegen, Netherlands
byondis.com Biotech Dutch drug developer working on ADCs, including conditionally activated conjugates and antifolate payloads.	Also Presenting at the meeting, on no published session yet
CanWell Pharma Woburn, MA
canwellpharma.com Biotech Develops dual- and multi-payload ADCs on its StarLinker platform, plus TLR7 immune-agonist programs for cancer.	Also Presenting at the meeting, on no published session yet
Debiopharm Lausanne, Switzerland
debiopharm.com Biotech Swiss privately owned drug developer in oncology and infectious disease, with its MultiLINK technology for ADC design.	Also Presenting at the meeting, on no published session yet
Hummingbird Bioscience Singapore
hummingbirdbioscience.com Biotech Develops antibody therapeutics and antibody-drug conjugates for cancer and autoimmune diseases.	Also Presenting at the meeting, on no published session yet
ONA Therapeutics Barcelona, Spain
onatherapeutics.com Biotech Barcelona biotech developing antibody-based cancer therapies, including ADCs, that target lipid metabolism in metastasis.	Also Presenting at the meeting, on no published session yet
Biocytogen Beijing, China	◇Exhibition Partner
biocytogen.com BiotechExhibition Partner Discovers fully human antibodies on its mouse platforms for partners, and supplies humanized animal models and pharmacology services for antibody and ADC programs.	Sponsor In the meeting’s sponsor directory, with no session on the public program